MiNK Therapeutics reported a net loss of $8.4 million for the first nine months of 2026, an improvement from the $9.9 million loss in the prior year period. The company recorded its first pre-commercial product revenue of $200,000 and maintained a cash balance of $7.5 million as of September 30, 2026.
MiNK Therapeutics reported third quarter 2026 financial results, highlighting its first pre-commercial product revenue from agenT-797 via an international named-patient access program. The company also noted its selection for an ARPA-H program with up to $87 million in team-wide funding and the advancement of its randomized Phase 2 ARDS trial.
Term
Q3 2026
“We now have a randomized trial running in critical illness, multiple clinical programs enrolling and a path toward pivotal development. This quarter, physicians outside our trials began requesting agenT-797 for their patients, bringing our first pre-commercial revenue. The same unmodified iNKT cells, from the same donor, that drove a 77% disease control rate in PD-1-refractory gastroesophageal cancer are now in a placebo-controlled trial in ARDS, where nearly four in ten patients die and no effective approved drug changes that outcome. Our focus now is delivering the randomized readout designed to show what these cells can do for these patients.”
Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics
MiNK Therapeutics CEO Jennifer Buell Sells $73.3K of Stock
Jennifer Buell, CEO, sold 6,938 shares of MiNK Therapeutics, Inc. at $10.56 a share, worth $73.3K in total on Oct 12, 2026. Shares held after the trade: 74,195 (-8.6%).